Neoadjuvant PD-1 blockade with dostarlimab achieved high rates of organ preservation in patients with early-stage mismatch repair-deficient (dMMR) solid tumors across multiple types. Most patients avoided surgery with durable disease control, reshaping potential cancer treatment pathways.